Regulatory Information
APEX PHARMA MARKETING PTE. LTD.
APEX PHARMA MARKETING PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
SUSPENSION
**Dosage and Administration** To be administered orally. By body weight:6 mg Trimethoprim plus 30mg Sulphamethoxazole per kg body weight per dayChildren 6 weeks to 5 months:2.5 ml, every 12 hours6 months to 5 years:5 ml, every 12 hours6 to 12 years:10 ml, every 12 hours.
ORAL
Medical Information
**Indications** Treatment of infections caused by susceptible organisms, as in: respiratory tract infections, urinary tract infections, gastro-intestinal tract infections, including typhoid and paratyphoid fever; cholera; skin and soft tissues infections; brucellosis (generally in combination with other agents), septicaemia due to sensitive organisms, nocardiosis, mycetoma (except when caused by the true fungi). For South American blastomycosis, **BS** is suppressive but not curative.
**Contraindications** **BS** should not be used in patients with marked liver parenchymal damage; severe renal insufficiency; or patients with serious megaloblastic bone marrow; or patients with documented megaloblastic anemia due to folate deficiency. **BS** is contraindicated in patients with a known hypersensitivity to trimethoprim or sulphonamides, in patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulphonamides. Its use in pregnancy should be avoided, unless the expected therapeutic benefits outweigh the possible risks. **BS** should not be used in nursing mothers. **BS** is contraindicated in premature and newborn infants within 1 to 2 months of birth because of the risk of producing kernicterus.
J01EE01
sulfamethoxazole and trimethoprim
Manufacturer Information
APEX PHARMA MARKETING PTE. LTD.
XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD